Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$288.9MCash, Jun 2026
24moCash Runway (est.)
+28%Share Count, 1 Year
Follow LYEL by emailGet an email when LYEL pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about LYEL, unsubscribe in one click. Privacy
📣 What LYEL Says Is Next
in 2027 · “Additional clinical data from the trial and a planned End-of-Phase 1 meeting with the FDA are now expected in 2027.”
Company press release, Sep 10, 2026 · SEC filing
second half of 2026 · “Additional U.S. Phase 1 clinical data in patients with R/R mCRC in the 3L+ setting and an End-of-Phase 1 meeting with the FDA are expected in the second half of 2026.”
Company press release, Aug 6, 2026 · SEC filing
second half of 2026 · “Additional data from this trial are expected in the second half of 2026, and pivotal data are expected in mid-2027 with submission of a Biologics License Application (BLA) to the FDA expected to follow in the second half of 2027.”
Company press release, Aug 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
LYEL reported $288.9M in cash and short-term investments (as of Jun 30, 2026) and used about $36.5M/quarter in operations, an estimated runway of 23.7 months at that rate (BioRadar estimate, not company guidance).
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LYEL and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.